Study Name:
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Targeted Disease(s):
Lung Cancer
Study Dates:
February 5, 2021 - January 1, 2025
Type of Study:
Pre-Market
Study Location:
Nationwide
Lead Institution:
Advent Health Cancer Institute, Florida
Funding Source:
BeiGene
ClinicalTrails.gov Identifier:
NCT04746924
Conacts:
BeiGene
Phone number 1-877-828-5568
Email address clinicaltrials@beigene.com
